Q2 2013 · —
Revenue$208.25M$208.25M +67.6% vs Q2 2012+6.1% vs Q1 2013
Net Income$42.19M$42.19M +55.4% vs Q2 2012−2.9% vs Q1 2013
EPS Diluted$0.69$0.69 +53.3% vs Q2 2012−2.8% vs Q1 2013
Gross Profit$181,533,000+64.0%
Operating Income$77,066,000+95.5%
Operating Cash Flowderived$8,719,000−88.7%
Free Cash Flowderived$5,152,000−93.1%
Margins · derived
Gross margin87.2%−1.9 pt vs Q2 2012
Operating margin37.0%+5.3 pt vs Q2 2012
Net margin20.3%−1.6 pt vs Q2 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2013 | Q2 2012 | Q2 2011 | Q2 2010 |
|---|---|---|---|---|
| Revenue | $208.25M | $124.23M | $64.57M | $64.57M |
| Net Income | $42.19M | $27.15M | $33.20M | $33.20M |
| EPS Diluted | $0.69 | $0.45 | $0.71 | $0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR